The median follow-up time (and range) for childhood AML alive at last contact was 2.9 (0.1–10.9) years for patients with mutant FLT3/ITD and 3.6 (0.1–11.3) years for those with wild-type (P < 0.001). This evidence concerns the gene FLT3 and acute myeloid leukemia.